Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index110
i10-index489
Publications1,170
Citations49,298

Grants

48 total · 5 active

NIH #5R01CA262292-05

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$608K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA262292-04

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$605K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA262292-03

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$572K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

48 total · 5 active

NIH #5R01CA262292-05

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$608K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA262292-04

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$605K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA262292-03

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$572K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA262292-02

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$579K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #1R01CA262292-01A1

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$505K
Period
2022-06-01 → 2027-05-31
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #5R01CA247471-05

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$573K
Period
2019-12-20 → 2026-05-31
PIs
3
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #5R01CA247471-04

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$535K
Period
2019-12-20 → 2025-05-31
PIs
3
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #5R01CA247471-03

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$535K
Period
2019-12-20 → 2024-11-30
PIs
3
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #5R01CA247471-02

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$568K
Period
2019-12-20 → 2024-11-30
PIs
3
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #1R01CA247471-01

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$615K
Period
2019-12-20 → 2024-11-30
PIs
3
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #5R01CA129501-05

Role of Paxillin in Lung Cancer

Amount
$318K
Period
2008-06-02 → 2014-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5P01HL058064-17

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$301K
Period
— → 2014-01-31
PIs
1
Est. capacity / PI
~5 students

Awarded at UNIVERSITY OF ILLINOIS AT CHICAGO

NIH #5R01CA129501-04

Role of Paxillin in Lung Cancer

Amount
$318K
Period
2008-06-02 → 2013-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA129501-03

Role of Paxillin in Lung Cancer

Amount
$328K
Period
2008-06-02 → 2013-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA129501-02

Role of Paxillin in Lung Cancer

Amount
$327K
Period
2008-06-02 → 2013-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #1R01CA129501-01A1

Role of Paxillin in Lung Cancer

Amount
$327K
Period
2008-06-02 → 2013-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-09

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$241K
Period
2004-03-01 → 2013-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-08

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$241K
Period
2004-03-01 → 2013-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-07

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$248K
Period
2004-03-01 → 2013-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-06

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$251K
Period
2004-03-01 → 2013-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #2R01CA100750-05A1

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$258K
Period
2004-03-01 → 2013-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5P01HL058064-16

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$301K
Period
2011-02-01 → 2013-01-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF ILLINOIS AT CHICAGO

NIH #2P01HL058064-13

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$360K
Period
2008-02-01 → 2013-01-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA125541-05

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$255K
Period
2007-01-15 → 2012-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #3R01CA129501-02S1

Role of Paxillin in Lung Cancer

Amount
$187K
Period
2008-06-02 → 2012-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R21CA140003-02

Novel Targeted Therapy in Pancreatic Cancer

Amount
$206K
Period
2009-03-01 → 2012-02-28
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA125541-04

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$262K
Period
2007-01-15 → 2011-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA125541-03

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$262K
Period
2007-01-15 → 2011-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA125541-02

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$262K
Period
2007-01-15 → 2011-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #1R01CA125541-01

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$262K
Period
2007-01-15 → 2011-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #1R21CA140003-01

Novel Targeted Therapy in Pancreatic Cancer

Amount
$172K
Period
2009-03-01 → 2011-02-28
PIs
2
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #3R01CA100750-06S1

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$19K
Period
2004-03-01 → 2010-09-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #3R01CA125541-03S1

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$98K
Period
2009-08-01 → 2010-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-04

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$237K
Period
2004-03-01 → 2008-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-03

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$244K
Period
2004-03-01 → 2008-02-29
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #5R01CA100750-02

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$250K
Period
2004-03-01 → 2008-02-29
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #1R01CA100750-01A1

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$250K
Period
2004-03-01 → 2008-02-29
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF CHICAGO

NIH #3R21CA081324-02S1

MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER

Amount
$2K
Period
1999-04-05 → 2003-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R29CA075348-05

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$118K
Period
1997-08-01 → 2002-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R29CA075348-04

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$118K
Period
1997-08-01 → 2002-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R29CA075348-03

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$118K
Period
1997-08-01 → 2002-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R29CA075348-02

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$117K
Period
1997-08-01 → 2002-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1R29CA075348-01

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$117K
Period
1997-08-01 → 2002-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5K08CA060821-03

PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN

Amount
$88K
Period
1993-08-15 → 1996-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5K08CA060821-02

PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN

Amount
$77K
Period
1993-08-15 → 1996-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1K08CA060821-01

STUDIES OF PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN

Amount
$82K
Period
1993-08-15 → 1996-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #7P01HL058064-15

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$361K
Period
— → —
PIs
1
Est. capacity / PI
~6 students

Awarded at UNIVERSITY OF ILLINOIS AT CHICAGO

NIH #5P01HL058064-14

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$353K
Period
— → —
PIs
1
Est. capacity / PI
~5 students

Awarded at UNIVERSITY OF CHICAGO

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 67
Open author page on OpenAlex →